Introduction
Medial epicondylitis, commonly known as "golfer’s elbow," is a painful condition characterized by inflammation and micro-tearing at the common flexor tendon origin on the medial epicondyle. While conservative management—including rest, physical therapy, and non-steroidal anti-inflammatory drugs (NSAIDs)—is the first line of defense, local corticosteroid injections are frequently employed for rapid symptomatic relief when pain persists. Although generally considered safe, these injections are not without risk. This report details an extraordinary case of localized skin hypopigmentation and subcutaneous tissue atrophy following repeated steroid injections for medial epicondylitis.
Case Presentation
A 53-year-old female patient presented with a three-year history of chronic pain in her right medial elbow. Over the course of her treatment, she received three separate corticosteroid injections (betamethasone) at 6, 12, and 24 months after the initial onset of symptoms. Approximately nine months after the final injection, the patient noticed significant changes in the appearance and texture of the skin at the injection site.
Physical examination revealed a 1 x 1.5 cm area of distinct tissue atrophy and significant skin whitening (hypopigmentation) centered over the medial epicondyle. Despite these cosmetic and structural changes, the patient did not report neurological symptoms such as numbness or tingling in the ulnar nerve distribution.
Diagnostic Evaluation
To quantify the extent of the damage and rule out neurological complications, several diagnostic modalities were employed:
- Ultrasonography: Transverse ultrasound imaging was performed to compare the affected right elbow with the healthy left elbow. The imaging confirmed a significant reduction in the thickness of the subcutaneous tissue and the pronator teres (PT) muscle on the affected side. This provided objective evidence of the "denting" observed clinically.
- Electrophysiology: Given the proximity of the ulnar nerve to the medial epicondyle, nerve conduction studies were vital. Results indicated normal motor and sensory conduction velocities, confirming that the ulnar nerve remained unaffected by the steroid-induced atrophy.
- Dermatological Consultation: Specialist review confirmed that the skin changes were consistent with steroid-induced pigmentary inhibition rather than permanent cell death.
Discussion of Pathogenesis
The mechanisms behind these complications involve both cellular inhibition and physical drug distribution:
The "Lymphatic Spread" Hypothesis
The authors suggest that corticosteroid crystals may migrate through lymphatic channels. This phenomenon explains why hypopigmentation can sometimes appear in a linear pattern or extend well beyond the immediate needle track, as seen in this case.
Cellular Inhibition vs. Death
Steroid-induced hypopigmentation is primarily caused by the functional inhibition of melanocytes rather than their destruction. Corticosteroids interfere with the production and release of melanin. Similarly, the observed atrophy results from the inhibition of keratinocytes and fibroblasts, which disrupts protein metabolism and lipid synthesis in the skin and underlying muscle layers.
Drug Solubility
While this case involved betamethasone, the literature suggests that long-acting, low-solubility preparations (such as triamcinolone acetonide) are more frequently associated with these side effects due to their prolonged presence in the local tissue.
Clinical Recommendations and Conclusion
While steroid-induced atrophy and hypopigmentation often resolve spontaneously within 9 to 12 months, they cause significant psychological and cosmetic distress. To minimize these risks, the authors propose the following clinical guidelines:
- Ultrasound Guidance: Utilizing real-time imaging ensures the steroid is delivered precisely to the target tendon, preventing accidental "splash" into the subcutaneous fat or skin layers.
- Volume Control: For upper extremity soft tissue, a volume of 0.5–2 mL is generally sufficient. Exceeding this volume increases the risk of local pressure and drug dispersion into unintended tissues.
- Dosing Intervals: Clinicians should exercise caution with repeated injections. If a patient requires more than two injections, alternative modalities such as extracorporeal shockwave therapy (ESWT) or surgical consultation should be considered.
This case serves as a critical reminder that even routine clinical procedures require meticulous technique and a thorough understanding of potential cumulative side effects.
Summary updated